Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

New Eli Lilly acquisition to progress potential next-generation pain treatment

5
SHARES

The deal will support Eli Lilly and Company to advance non-opioid medicines and expand its pain therapy pipeline.

Eli Lilly SiteOne Therapeutics acquisition STC-004 chronic pain

Eli Lilly and Company has agreed to acquire the biotech SiteOne Therapeutics, Inc. Shareholders of SiteOne will be eligible for a total of $1.0 billion in cash. The deal includes the Phase II-ready oral NaV1.8 inhibitor STC-004, which is being evaluated as a chronic pain medicine.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Lilly stated that the investigational drug could represent a next-generation option for these patients. Phase I results showed that in treating chronic pain, STC-004 has significant analgesic potential, it was well-tolerated and is appropriate for once-daily oral administration at a low dosage.

What does Eli Lilly’s acquisition of SiteOne Therapeutics include?

Under the new agreement, the financial considerations are inclusive of payments on the basis that certain regulatory and commercial milestones are achieved. The transaction is subject to customary closing conditions.

[Currently,] an effective non-opioid treatment for chronic pain remains elusive”. 

Mark Mintun, Eli Lilly group Vice President, Neuroscience Research and Development, explained that an effective non-opioid treatment for chronic pain “remains elusive”. 

As such, the pharmaceutical company is eager to continue development of the NaV1.8 inhibitor STC-004 “as part of our efforts to advance novel, addiction-free pain therapies,” Mintun added. This new agreement between Lilly and SiteOne therefore supports this mission.

Eli Lilly – investing in medicine advancement

Earlier this month, Lilly announced the expansion of its long-term partnership with Purdue University, committing up to $250 million by 2032. With a goal to accelerate innovation in the pharmaceutical pipeline, this collaboration has potential to be the largest industry-academic agreement in US history.

In December 2024, Lilly revealed another agreement to advance pharmaceutical product development, specifically with external biotech collaborators. The collaboration is in partnership with the contract development and manufacturing organisation (CDMO) Cambrex. As part of the agreed terms, collaborators will have access to different areas of the facility including process development, manufacturing and analytical development.

Share via
Share via